A group of multinational pharmaceutical executives, such as BMS and AbbVie, have left

(2020/09/09) The top 10 most popular biosynthic drugs in China have 20 plus enterprises competing; Lost the standard varieties hit the performance of pharmaceutical enterprises innovation "firepower all open", Wanta biological real controller Zhong8 once climbed to the top of the domestic richest ... (Click on the title to get the original article) "Pharmaceutical 1st Time" Executive Season: BMS Head of Oncology Research and Development Joins Blueprint, AbbVie Veteran to Join Magenta Foreign Biotechnology Website Fierce Biotech Personnel Change Column Chutes andamp; Ladders recently released a summary of recent personnel changes in the biopharmaceutical industry, which Sina Pharmaceuticals compiled: BMS Head of Oncology Research and Development joins Blueprint, AbbVie veteran joins Magenta Therapeutics, Sage Therapeutics Clinical Development Head Joins Nocion Therapeutics... Headline: Why? Mina network: collection impact! The loss of the standard varieties hit the performance of pharmaceutical enterprises innovation "firepower all open" with the disclosure of listed companies, the impact of national collection on the performance of pharmaceutical enterprises also surfaced.
against the background of the impact of the New Crown epidemic on the economy and the acceleration of the normalization of national collection, the performance of focus enterprises such as Huahai, East China, Xinlitai and Jingxin in the first half of 2020 has attracted much attention from the industry.
as the winner of the 4-plus-seven episode, Huahai and Beijing-New 2019H1 have benefited greatly, while the change in the 4-plus-seven expansion has divided the two performances.
headlines: "Barefoot" companies are both grabbing the market and making a profit.
the traditional target XPO1 for multiple myeloma be the next wind? Of the Top 100 varieties of global drug sales in 2019, there are four varieties with multiple myeloma, namely, lynamine (nearly $9.4 billion), Daratumumab (nearly $3 billion), Pomadamine (nearly $2.2 billion), and boronazome (nearly $1.9 billion); Large share, and the target, drug category, treatment means have been initially stable, in this context, XPO1 inhibitors successfully completed the target and variety of verification, and a new mechanism of action into the multiple myeloma market, high attention, and domestic start-up Deqi Pharmaceuticals to obtain the relevant varieties of the Greater China region development rights, the target and its inhibitor future prospects, it is more worthy of fine taste! Headline bacteria: targeted XPO1 is currently also used for the development of clinical trials of the new crown yo "Medical Valley" Wantay biological real controller clock 8 at one point the top of the domestic richest person on September 8, Farmer Shanquan listed on the Hong Kong Stock Exchange, the opening price of 38.8 Hong Kong dollars / share, compared with the issue price of 21.5 Hong Kong dollars / share, a jump of 85.12%.
Zhong the founder and chairman of Farmer's Mountain Springs, owns 84.4 per cent, and at today's opening price, Chungwas once worth $57.4 billion, surpassing Ma Huateng as China's new richest man, according to Forbes.
headlines: only half a day to be the richest.
Insight Database: The top 10 biosynthic drugs in China have more than 20 enterprises competing since February 2015, when the State Drug Administration formulated and issued the Technical Guidelines for the Development and Evaluation of Biosynthic Drugs (Trial), the development of biosynthic drugs in China has gradually entered the right track, and is now in the country with the largest number of biosynthic drugs.
: Domestic biosynthic drugs enter a golden age.